Our laboratory is interested in understanding how epigenetic aberrations cause cancer and other human diseases. In particular, we focus on the roles and regulatory mechanisms of histone demethylases from the JARID1/KDM5 protein family. These enzymes can remove tri- and di- methyl mark from lysine 4 in histone H3 (H3K4me3/2), the epigenetic marks for transcriptionally active chromatin. Our current data suggest that JARID1A/B enzymes are potential drug targets for cancer therapy and we have identified specific inhibitors of these enzymes.
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.